Treatment choices and neuropsychological symptoms of a large cohort of early MS

von Bismarck, Olga; Dankowski, Theresa; Ambrosius, Björn; Hessler, Nicole; Antony, Gisela; Ziegler, Andreas; Hoshi, Muna-Miriam; Aly, Lilian; Luessi, Felix; Groppa, Sergiu; Klotz, Luisa; Meuth, Sven G.; Tackenberg, Björn; Stoppe, Muriel; Then Bergh, Florian; Tumani, Hayrettin; Kümpfel, Tania; Stangel, Martin; Heesen, Christoph; Wildemann, Brigitte; ... (2018). Treatment choices and neuropsychological symptoms of a large cohort of early MS. Neurology: Neuroimmunology and Neuroinflammation, 5(3), e446. Wolters Kluwer Health 10.1212/NXI.0000000000000446

[img]
Preview
Text
e446.full.pdf - Published Version
Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND).

Download (416kB) | Preview

Objective: To assess clinical characteristics, distribution of disease-modifying treatments (DMTs), and neuropsychological symptoms in a large cohort of patients with early-stage MS. Methods: The German National MS Cohort is a multicenter prospective longitudinal cohort study that has recruited DMT-naive patients with clinically isolated syndrome (CIS) and relapsing-remitting MS (RRMS) since 2010. We evaluated their baseline characteristics and the prevalence of neuropsychological symptoms. Results: Of 1,124 patients, with a 2.2:1 female-to-male ratio and median age at onset of 31.71 years (interquartile range [IQR]: 26.06–40.33), 44.6% and 55.3% had CIS and RRMS, respectively. The median Expanded Disability Status Scale (EDSS) score at baseline was 1.5 (IQR: 1.0–2.0). A proportion of 67.8% of patients started DMT after a median time of 167.0 days (IQR 90.0–377.5) since the first manifestation. A total of 64.7% and 70.4% of the 762 patients receiving early DMT were classified as CIS and RRMS, respectively. Fatigue, depressive symptoms, and cognitive dysfunction were detected in 36.5%, 33.5%, and 14.7% of patients, respectively. Conclusion: Baseline characteristics of this large cohort of patients with early, untreated MS corroborated with other cohorts. Most patients received early DMT within the first year after disease onset, irrespective of a CIS or RRMS diagnosis. Despite the low EDSS score, neuropsychological symptoms affected a relevant proportion of patients.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Neurology

UniBE Contributor:

Salmen, Anke

Subjects:

600 Technology > 610 Medicine & health

ISSN:

2332-7812

Publisher:

Wolters Kluwer Health

Language:

English

Submitter:

Stefanie Hetzenecker

Date Deposited:

18 Apr 2018 12:05

Last Modified:

22 Apr 2018 02:22

Publisher DOI:

10.1212/NXI.0000000000000446

PubMed ID:

29511705

BORIS DOI:

10.7892/boris.112424

URI:

https://boris.unibe.ch/id/eprint/112424

Actions (login required)

Edit item Edit item
Provide Feedback